Economic assessments conducted in the UK further support the cost-effectiveness of adalimumab and other anti-TNF agents compared with conventional therapy for treating patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA) [83]. Here, TNF is linked to ankylosing spondylitis.